ONESOURCE1,548.10

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,744 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ONESOURCE
FY26
STAR
FY26
DIVISLAB
FY26
GLAND
FY26
Peer
Median
Valuation — at last close
P/E20.07×97.31×47.31×47.31×
P/B3.04×3.54×14.89×4.69×4.69× -35%
EV/EBITDA62.39×13.66×72.47×27.91×27.91× +123%
Market Cap₹17,744 Cr₹11,162 Cr₹2.49L Cr₹48,604 Cr₹48,604 Cr -63%
Growth
Revenue CAGR 3Y9.62%10.78%21.06%10.78%
Revenue CAGR 5Y7.94%8.67%13.18%8.67%
Net Income CAGR 3Y12.09%9.57%10.83%
Revenue YoY (latest Q)37.20%13.01%27.80%19.57%19.57% +90%
Net Income YoY (latest Q)13539.25%56.73%65.50%47.09%56.73% +23766%
Profitability
EBITDA Margin21.40%19.04%32.59%25.34%25.34% -16%
Net Income Margin-5.19%11.82%24.32%15.98%15.98% -132%
Return on Common Equity-1.27%17.66%15.32%9.92%15.32% -108%
Return on Capital Employed0.37%17.93%16.55%11.06%16.55% -98%
Return on Assets-0.90%8.29%12.82%8.21%8.29% -111%
Credit & Quality
Total Debt/Equity0.22×0.53×0.00×0.02×0.02× +1000%
Interest Coverage0.21×4.05×129.48×36.24×36.24× -99%
Scale — latest FY
Revenue / Total Income₹1,422 Cr₹4,859 Cr₹10,560 Cr₹6,431 Cr₹6,431 Cr -78%
Net Income−₹73.8 Cr₹575 Cr₹2,568 Cr₹1,027 Cr₹1,027 Cr -107%
Total Assets₹8,210 Cr₹6,927 Cr₹20,033 Cr₹12,511 Cr₹12,511 Cr -34%
EPS₹-6.44₹60.34₹96.75₹62.35₹62.35 -110%
Book Value per Share₹508.75₹341.68₹632.49₹628.67₹628.67 -19%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.